lunes, 5 de junio de 2017

Press Announcements > FDA expands use of Sapien 3 artificial heart valve for high-risk patients

Press Announcements > FDA expands use of Sapien 3 artificial heart valve for high-risk patients

u s food and drug administration



06/05/2017 03:44 PM EDT


The U.S. Food and Drug Administration today approved an expanded indication for the Sapien 3 Transcatheter Heart Valve (THV) for patients with symptomatic heart disease due to failure of a previously placed bioprosthetic aortic or mitral valve whose risk of death or severe complications from repeat surgery is high or greater.

No hay comentarios:

Publicar un comentario